By Ben Hirschler AMSTERDAM (Reuters) - An experimental heart failure drug from Amgen and Cytokinetics missed its goal of improving shortness of breath in a mid-stage clinical trial, leaving its future uncertain. Despite the setback in the 613-patient trial using an intravenous formulation of the medicine omecamtiv mecarbil in hospitals, Amgen said it would continue testing an oral version of the drug in a separate Phase II study. The combined results from the tests will determine whether the medicine advances into final Phase III testing or is discontinued. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment